Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Reclassifying myelodysplastic syndromes: what's where in the new WHO and why.

Hematology. American Society of Hematology. Education Program - 1 Jan 2015

Arber Daniel A, Hasserjian Robert P

Abstract excerpt

A revision to the 4th edition of the WHO Classification of myelodysplastic syndromes (MDSs), originally published in 2008, is expected in mid-2016. Based on recommendations of a Clinical Advisory Committee, the revision will aim to incorporate new discoveries in MDS that impact existing disease categories. Although the basic diagnostic principles of the WHO classification remain unchanged, several changes to the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anemia, Sideroblastic
Share to Cytogenetics
Share to Hematology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunophenotyping

Share to Myelodysplastic Syndromes

Share to Ribonucleoprotein, U2 Small Nuclear

Share to RNA Splicing Factors

Share to World Health Organization

Source

Identifiers

PMID: 26637736
DOI: 10.1182/asheducation-2015.1.294

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Reclassifying myelodysplastic syndromes: what's where in the new WHO and why.PMID 26637736Read ↗

Myelodysplastic Syndrome Updated.Semantic proximity Read ↗

The myelodysplastic syndromes: diagnosis, molecular biology and risk assessment.Semantic proximity Read ↗

Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.Semantic proximity Read ↗

An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasmsSemantic proximity Read ↗

[New insights into the nature and classification of myelodysplastic neopmasm].Semantic proximity Read ↗

The International Consensus Classification of myelodysplastic syndromes and related entities.Semantic proximity Read ↗

Diagnostics and Prognostication of Myelodysplastic SyndromesSemantic proximity Read ↗

Diagnosis and classification of myelodysplastic syndromesSemantic proximity Read ↗

[Classification and clinical findings of myelodysplastic syndromes].Semantic proximity Read ↗

The changing classification of myelodysplastic syndromes: what's in a name?Semantic proximity Read ↗

NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022.Semantic proximity Read ↗

Myelodysplastic syndromes: recent advancements in risk stratification and unmet therapeutic challenges.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.